Open AccessInterval cancer incidence and episode sensitivity in the Norrbotten Mammography Screening Programme, Sweden
Author(s) -
Pál Bordás,
Håkan Jonsson,
Lennarth Nyström,
Per Lenner
Publication year - 2009
Publication title -
journal of medical screening
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.515
H-Index - 64
eISSN - 1475-5793
pISSN - 0969-1413
DOI - 10.1258/jms.2009.008098
Subject(s) - medicine , incidence (geometry) , mammography , cancer , mammography screening , interval (graph theory) , sensitivity (control systems) , breast cancer , gynecology , mathematics , combinatorics , electronic engineering , engineering , physics , optics
Objectives To estimate the interval cancer incidence, its determinants and the episode sensitivity in the Norrbotten Mammography Screening Programme (NMSP).Setting Since 1989, women aged 40–74 years (n = 55,000) have been invited to biennial screening by the NMSP, Norrbotten county, Sweden.Methods Data on 1047 invasive breast cancers from six screening rounds of the NMSP (1989–2002) were collected. We estimated the invasive interval cancer rates, rate ratios and the episode sensitivity using the detection and incidence methods. A linear Poisson-model was used to analyse association between interval cancer incidence and sensitivity.Results 768 screen-detected and 279 interval cancer cases were identified. The rate ratio of interval cancer decreased with age. The 50–59 year age group showed the highest rate ratio (RR = 0.52, 95% CI 0.41–0.65) and the 70–74 year age group the lowest (RR = 0.23, 95% CI 0.15–0.36). The rate ratios for the early (0–12 months) and late (13–24 months) interval cancers were similar (RR = 0.18, 95% CI 0.15–0.22 and 0.20, 95% CI 0.17–0.24). There was a significantly lower interval cancer incidence in the prevalence round as compared with the incidence rounds. According to the detection method the episode sensitivity increased with age from 57% in the age group 40–49 years to 84% in the age group 70–74 years. The corresponding figures for the incidence method were 50% and 77%, respectively.Conclusion Our study showed an interval cancer incidence of 38% and the episode sensitivity of 62–73%, depending on the method of calculation. Our results are of clinically acceptable level and concert with the reference values of the European guidelines.